Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 5/20 | 0.41 |
| ▸ | CPA3 | P15088 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7335152 | 0.83 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7335142 | 0.83 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1798535 | 0.82 | SLC1A3 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1798536 | 0.82 | SLC1A3 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL29776962 | 0.76 | ALPI (0.46) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4795710 | 0.75 | ALPI (0.57) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4795705 | 0.75 | ALPI (0.57) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7422429 | 0.75 | ALPI (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7422432 | 0.75 | ALPI (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2927472 | 0.75 | SLC1A3 (0.45) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10793596-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10138270-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | CARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170007574-A1 | PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR UREMIC PRURITUS IN DIALYSIS PATIENTS | CARA THERAPEUTICS, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | CARA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| EP-2079756-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | Cara Therapeutics, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2064228-A2 | SYNTHETIC PEPTIDE AMIDES | Cara Therapeutics, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2008060552-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138270-B2 | Synthetic peptide amides | VIP, OPRK1, OPRL1 | ALPI 34/4885PKM 2398/4885PTGS1 164/4885 |
| US-20170007574-A1 | PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR UREMIC PRURITUS IN DIALYSIS PATIENTS | OPRK1, OPRL1, OPRD1 | ALPI 1390/4885PKM 2949/4885PTGS1 1944/4885 |
| US-20160376308-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | ALPI 1504/4885PKM 2427/4885PTGS1 228/4885 |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | OPRK1, OPRL1, OPRD1 | ALPI 813/4885PKM 2034/4885PTGS1 145/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | ALPI 843/4885PKM 2981/4885PTGS1 532/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | ALPI 880/4885PKM 2991/4885PTGS1 597/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | ALPI 34/4885PKM 2398/4885PTGS1 164/4885 |
| US-20090264373-A1 | of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma | OPRK1, OPRD1, OGFR | ALPI 13/4885PKM 2446/4885PTGS1 192/4885 |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | ALPI 34/4885PKM 2398/4885PTGS1 164/4885 |
| US-10913769-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | ALPI 1504/4885PKM 2427/4885PTGS1 228/4885 |
| US-20160310558-A1 | USES OF KAPPA OPIOID SYNTHETIC PEPTIDE AMIDES | OPRK1, OGFR, MMP13 | ALPI 56/4885PKM 2005/4885PTGS1 210/4885 |
| US-10017536-B2 | Synthetic peptide amides and dimers thereof | OPRK1, OPRL1, OPRM1 | ALPI 1504/4885PKM 2427/4885PTGS1 228/4885 |
| US-20190177365-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | OPRK1, OPRL1, OPRM1 | ALPI 1504/4885PKM 2427/4885PTGS1 228/4885 |
| US-10793596-B2 | Synthetic peptide amides | OPRK1, OPRL1, OPRD1 | ALPI 813/4885PKM 2034/4885PTGS1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.